MYB proto-oncogene like 2 (MYBL2)

MYB proto-oncogene like 2 (MYBL2), also known as B-Myb, is a highly conserved transcription factor in the MYB family that plays a vital role in regulating cell cycle progression, cell proliferation, survival, and differentiation[1][2][3][4][5][6]. Its activity is controlled across the cell cycle by post-transcriptional and post-translational mechanisms, including regulation by the DREAM and MuvB complexes, phosphorylation by cyclin A/E-CDK2, and ubiquitin-mediated degradation[1][2]. MYBL2 is essential for the transition through S and G2/M phases, genome stability, and maintenance of an undifferentiated, pluripotent cell state[1][2][4]. Overexpression of MYBL2 is strongly associated with poor prognosis in various cancers, and it contributes to tumor cell survival, cell cycle progression, and resistance to apoptosis[1][2][7]. While not commonly mutated in cancer, MYBL2’s dysregulation is central to tumorigenesis and represents an emerging therapeutic target, most feasibly through indirect network targeting such as reactivation of the tumor suppressor PP2A[1][2].

Other names

Myb-related protein BBMYBB-MybB-MYBMyb-like protein 2v-myb avian myeloblastosis viral oncogene homolog-like 2myb-related protein B

Indirect inhibition via PP2A activation leading to MYBL2 dephosphorylation and irreversible growth arrest in cancer cells